Drug Profile
Research programme: PET imaging agents - FluoroPharma
Alternative Names: [18F]AppCHFppA; AZPET; VasoPETLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Harvard Medical School; Massachusetts General Hospital
- Developer FluoroPharma
- Class Deoxy sugars; Imaging agents; Purines
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Atherosclerosis; Coronary disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis(Diagnosis) in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Coronary-disorders(Diagnosis) in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Alzheimer's-disease(Diagnosis) in USA (Parenteral)